2008: RA: Treatment and Pharmacosurveillance

RA: Treatment and Pharmacosurveillance

Monday, October 27, 2008

1005

Rapid Improvement in Work Productivity and Resource Utilization with anti-TNF Therapies in Real-World Practice: The Alberta Biologics Registry

1006

Improvements in Clinical Responses at Week 26 in Patients with Early Rheumatoid Arthritis Failing to Achieve a Clinical Response Following 12 Weeks of Etanercept or Methotrexate Treatment

1007

Safety and Efficacy of Etanercept (Enbrel^®) Treatment in North American Patients With Early and Long-Standing Rheumatoid Arthritis: 10 Years of Clinical Experience

1008

Tight Enough? Implementing TICORA in an Early Arthritis Clinic

1009

Methotrexate Therapy in Rheumatoid Arthritis Patients who Failed to Sulfasalazine Therapy: to Switch or to Add?

1010

No Increased Risk Of Solid Tumours In Patients Treated With Biologics

1011

Pregnancy Outcome in Women Exposed to Anti-TNF Agents: An Update from the British Society for Rheumatology Biologics Register (BSRBR)

1012

Decrease in Rheumatoid Factor and Anti-Citrullinated Protein Antibody Levels is associated with Response to Adalimumab Treatment in Patients with Rheumatoid Arthritis

1013

Trends in Admissions for Rheumatoid Arthritis during the TNF Inhibitor Era

1014

The Differential Effect Of Anti-tnf Therapy On The Risk Factors For Atherosclerosis Development Between Infliximab And Etanercept

1015

Mechanisms Of Anti-TNF-alpha Therapies Improvement On Insulin Sensitivity

1016

TNF Blocker Use and Cardiovascular Outcomes

1017

Methotrexate Polyglutamates and Disease Activity in Rheumatoid Arthritis

1018

Efficacy Of An Arch Pad With Ankle-strapping For Patients With Rheumatoid Arthritis And Metatarsalgia

1019

Golimumab, A New Human Anti-TNF-α Monoclonal Antibody Administered Subcutaneously Every 4 Weeks, Improves Anemia & Well-Being In Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Or Ankylosing Spondylitis

1020

Association Factors of Discontinuation of Antidepressant Medications in Patients with Rheumatoid Arthritis (RA) in A Large US Registry

1021

Likelihood of Maintaining or Increasing American College of Rheumatology Responses in Biologic-Naïve Patients Treated with Abatacept Plus Methotrexate: Insights from the AIM Trial

1022

Screening, Re-screening, and Treatment of PPD Positivity in Patients on Anti-TNF-alpha Therapy

1023

Tnf-α -308(a) Variant Predicts Poor Response To Tnfα Inhibitors In Rheumatoid Arthritis Patients: A Meta-analysis

1024

Characteristics of anti-TNF-treated RA patients with lymphoma. A report from the Swedish Biologics Register (ARTIS) 1998-2006

1025

Anti-TNF treated RA patients with Lymphoma: RA Course and treatment after Lymphoma diagnosis. A Report From The Swedish Biologics Register (ARTIS) 1998-2006

1026

Predicting Response To TNF Antagonists In Rheumatoid Arthritis: Results From The Lohren Clinical Registry

1027

Golimumab Significantly Improves Self-Reported Productivity in Patients with Rheumatoid Arthritis: Results from Three Phase III studies

1028

Examination Of Effects Of Tnf-alpha Antagonists On Arterial Stiffness In Patients With Rheumatoid Arthritis And Related Arthropathies: A Controlled Study

1029

Anti-tnf Treatment Improves Insulin Resistance In Rheumatoid Arthritis Patients: Clinical And Pathophysiological Correlates

1030

Genotyping Of Five Single Nucleotide Polymorphisms (SNP) Of Human NAT2 Gene By A Novel Diagnostic Microarray Platform Reveals An Increased Allele Frequency Of Slow Acetylation In Rheumatoid Arthritis Patients

1031

Treatment Compliance During Two Years Of Follow-up In A Cohort Of Early Rheumatoid Arthritis (era) Patients: Associated Factors And Relation With Disease Activity

1032

Comparison of QuantiFERON Gold Test and Tuberculin Skin Testing in patients undergoing screening for anti-TNF-alpha agents

1033

Effects of Low-dose Mizoribine Pulse Therapy in Combination with Methotrexate in Patients with Methotrexate-refractory Rheumatoid Arthritis

1034

Influences of Anti-TNF Agents on Healing of Surgical Wounds and Postoperative Recovery of Patients with Rheumatoid Arthritis

1035

Golimumab Significantly Improves Physical Function & Fatigue in RA Patients Previously Treated with Anti-TNFα Agents: Results from the GO-AFTER Study

1036

Health Utilities Improvement during TNF Blockade in Chronic Arthritis Occurs Early in the Treatment Course, Results from an Eight Year Observational Study in Southern Sweden

1037

Response to TNF Blockade after 6 Weeks Predicts Continuation of Therapy in Established RA. Results in an Observational Cohort from Southern Sweden

1038

Changes in IL-6, YKL-40 and VEGF during Adalimumab Treatment in Patients with active Rheumatoid Arthritis

1039

High Unmet Need for Arthritis Pain Management Among EU and US Rheumatoid Arthritis Patients Despite Effective Therapies

1040

Golimumab Significantly Improves Physical Function, Health-Related Quality of Life, and Fatigue in Rheumatoid Arthritis Patients: Results from the GO-FORWARD Study

1041

Effects Of Rituximab Treatment On Endothelial Dysfunction And Lipid Profile In Rheumatoid Arthritis

1042

Possible Reactivation Of Past HBV Infection by The Anti-TNF-α Blocker For The Treatment Of Rheumatic Diseases

1043

Beneficial Effect Of The Herbal Remedy Rose-hip On Patients With Rheumatoid Arthritis; Results Of A Randomized Double-blind Placebo-controlled Clinical Study

1044

Yellow Fever Vaccination During Infliximab Therapy

1045

The Effect of TNF Alpha Treatment on Lipid Profiles of Patients with Systemic Rheumatic Disease

1046

Weak Opioids Provide The Best Improvement Of Pain, Disease Activity And Related Disability In Rheumatoid Arthritis, Ankylosing Spondylitis And Psoriatic Arthritis Patients. Results Of A French Multicenter Cross Sectional Study

1047

Enzyme-linked Immunospot Assay Based Immunological Procedure is Useful for Diagnosis of Latent Tuberculosis in BCG Vaccinated Population: as a Screening before Anti-TNF Therapy

1048

Patients With Rheumatoid Arthritis Have Better Quality Of Life When Not Living Alone And This Is Not Related To Physical Dependence

1049

Physician-defined Remission in RA ("Disease activity: none") in the Swedish RA Registry: Relationship with DAS28 and ACR Core Set Variables

1050

The Value Of Patient Self Assessment Of Joints In Rheumatoid Arthritis

1051

Incidence of Liver Enzyme Elevations and Liver Biopsy Abnormalities During Methotrexate Treatment in Rheumatoid Arthritis: a Systematic Review of the Literature

1052

A Risk Assessment Of Nontuberculous Mycobacteriosis During Tnf Blocking Therapies For Rheumatoid Arthritis

1053

A Monitoring Of Patients With Hepatitis B Serological Pattern Indicating Past Infection And Treated By Tnfα Inhibitor For Inflammatory Rheumatism: Preliminary Results

See more of: ACR Abstract Submission Poster Sessions

<< Previous Session Level | Next Session Level >>